Literature DB >> 17314272

Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma.

Subhra Mohapatra1, Domenico Coppola, Adam I Riker, W Jack Pledger.   

Abstract

The aim of this study was to investigate the therapeutic potential of a cyclin-dependent kinase inhibitor, roscovitine, in cultured melanoma cells and a three-dimensional skin reconstruction model of metastatic melanoma. The modulatory effects of roscovitine on the growth and survival of normal melanocytes and cultured melanoma cell lines were tested. Additionally, we investigated the potential of roscovitine to regulate the growth and differentiation of a metastatic melanoma cell line (A375) in a three-dimensional skin reconstruction culture consisting of A375 cells admixed with normal human keratinocytes embedded within a collagen-constricted fibroblast matrix. We show that roscovitine is able to induce apoptosis in the melanoma cell lines A375, 888, and 624 but not in normal human cultured epithelial melanocytes. The degree of apoptosis within these cell lines correlated with the accumulation of p53 protein and concomitant reduction of X-linked inhibitor of apoptosis protein, with no change in the proteins Bcl-2 and survivin. We also found that roscovitine inhibited the growth and differentiation of A375 melanoma cells within the dermal layer of the skin. The results of this study show that roscovitine has the potential to inhibit the differentiation and invasion of metastatic melanoma and may be useful as a therapy for the treatment of patients with metastatic melanoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314272     DOI: 10.1158/1541-7786.MCR-06-0300

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  9 in total

1.  The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.

Authors:  Wei Fu; Le Ma; Baoky Chu; Xue Wang; Marilyn M Bui; Jennifer Gemmer; Soner Altiok; W Jackson Pledger
Journal:  Mol Cancer Ther       Date:  2011-04-13       Impact factor: 6.261

Review 2.  In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening.

Authors:  Xiao Hua Ma; Zhe Shi; Chunyan Tan; Yuyang Jiang; Mei Lin Go; Boon Chuan Low; Yu Zong Chen
Journal:  Pharm Res       Date:  2010-03-11       Impact factor: 4.200

Review 3.  Human skin models: From healthy to disease-mimetic systems; characteristics and applications.

Authors:  Tânia Moniz; Sofia A Costa Lima; Salette Reis
Journal:  Br J Pharmacol       Date:  2020-08-19       Impact factor: 8.739

4.  The effect of the combined action of roscovitine and Paclitaxel on the apoptotic and cell cycle regulatory mechanisms in colon and anaplastic thyroid cancer cells.

Authors:  V V Pushkarev; O I Kovzun; V M Pushkarev; M D Tronko
Journal:  ISRN Biochem       Date:  2012-08-30

Review 5.  Skin models for the testing of transdermal drugs.

Authors:  Eman Abd; Shereen A Yousef; Michael N Pastore; Krishna Telaprolu; Yousuf H Mohammed; Sarika Namjoshi; Jeffrey E Grice; Michael S Roberts
Journal:  Clin Pharmacol       Date:  2016-10-19

6.  Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.

Authors:  Serena Vella; Elisa Tavanti; Claudia Maria Hattinger; Marilù Fanelli; Rogier Versteeg; Jan Koster; Piero Picci; Massimo Serra
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

7.  Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFκB signaling pathways.

Authors:  Harish Chandra Pal; Samriti Sharma; Leah Ray Strickland; Santosh K Katiyar; Mary E Ballestas; Mohammad Athar; Craig A Elmets; Farrukh Afaq
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

8.  Screening and identification of small molecule inhibitors of ErbB2-induced invasion.

Authors:  D M Brix; B Rafn; K Bundgaard Clemmensen; S H Andersen; N Ambartsumian; M Jäättelä; T Kallunki
Journal:  Mol Oncol       Date:  2014-07-12       Impact factor: 6.603

9.  Accumulation of prohibitin is a common cellular response to different stressing stimuli and protects melanoma cells from ER stress and chemotherapy-induced cell death.

Authors:  Tharcisio Citrangulo Tortelli; Lyris Martins Franco de Godoy; Gustavo Antonio de Souza; Diego Bonatto; Andreia Hanada Otake; Renata de Freitas Saito; Jose Cesar Rosa; Lewis Joel Greene; Roger Chammas
Journal:  Oncotarget       Date:  2017-06-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.